Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combination Therapies (ACTs) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria

NCT05951595 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT05951595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combination Therapies (ACTs) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Lead sponsor
University of Oxford
Phase
Phase 3
Overall status
Recruiting
Start date
September 11, 2025
Completion date
July 31, 2026
Enrollment
1,680 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uncomplicated plasmodium falciparum malaria